92% of Vernalis is owned by institutional investors with Woodford and Invesco owning over 50% between them. Vernalis has significant products to help with migraine and even the common cold.These are at advanced stages of development in America. The future revenue stream will be in US dollars.Broker targets are over 91p. Be happy
comparing minnow Sar rising 22%, the share price of VER is still falling, anyone reckon this will touch the 20s range back in 2104? What's the real reason of the falling share price, is it the huge sales cost and the very moderate revenue income reported in the half yearly results?
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.